Giovanni Blandino, MD
Regina Elena Cancer Institute, Rome, Italy.
Dr. Blandino graduated with Master Degree from University of Catania, Italy in 1990. He received High School degree in Oncology from the University of Milan, 1994. He performed his postdoctoral research activities at the Weizmann Institute of Science, Israel from 1995-1999.
He is now Head of the Oncogenomic and Epigenetic Unit at Regina Elena Cancer Institute in Rome and Adjunct Associate Professor at the Department of Oncology, at the McMaster University, in Hamilton, Canada.
In aggregate, over the past twenty years much of his experimental, translational and clinical work has focused on the molecular understanding of the oncogenic role of mutant p53 proteins. At the present time, TP53 is the most studied tumor suppressor gene and it is the most frequent target for genetic alterations in human cancers. Because the frequency of TP53 mutations ranges from 50 to 70% of human cancers, TP53 protein has become the focus of very intense experimental and clinical cancer research. His research group has originally found that gain of function mutant TP53 proteins exert their oncogenic activities physically interacting with bona-fide transcription factors such as NF-Y, E2Fs, and thereby promotes aberrant transcription of genes involved in cell proliferation, invasion, migration and genomic instability. His group originally reported that gain of function mutant TP53 proteins modulate aberrantly the expression of Non-Coding Factors such microRNAs, circularRNAs. In addition to the TP53, his major current research focus is translational implications of small non- coding RNAs (microRNAs and circular RNAs) that are emerging as epigenetic powerful biomarkers for fine molecular stratification of human cancer, for its prevention, early detection and prediction of response to cancer treatment.